Cytotoxic Effects of Bee Venom-loaded ZIF-8 Nanoparticles on Thyroid Cancer Cells: a Promising Strategy for Targeted Therapy

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 19

PMID 39699709

Authors

Hasan Ilhan

Dilek Kabakci

Mucahit Secme

Affiliations

Soon will be listed here.

Abstract

Thyroid cancer continues to be a notable health issue, requiring the creation of novel treatment methods to enhance patient results. The objective of this study is to investigate the potential of utilizing bee venom (BV)-loaded zeolitic imidazolate framework-8 (ZIF-8) nanoparticles as a novel strategy for specifically targeting and treating medullary thyroid cancer cells. Due to their wide surface area and configurable pore size, ZIF-8 nanoparticles are ideal for drug delivery. Bee venom's cytotoxic capabilities are used in ZIF-8 nanoparticles to target thyroid cancer cells more effectively. ZIF-8 nanoparticles containing bee venom were tested on TT medullary thyroid cancer cell lines. The effects of these nanoparticles on cell viability, proliferation, and apoptosis were investigated. IC value at 24 h for BV-ZIF-8 nanoparticles in TT medullary thyroid carcinoma cells was determined to be 17.19 µg/mL, while the IC value at 48 h was determined to be 16.39 µg/mL. It has been demonstrated that nanoparticle treatment upregulates the Bax and caspase-3 genes while downregulating the Bcl-2, CCND1, and CDK4 genes. Additionally, it was observed that oxidative stress was triggered in the nanoparticle-treated group. Furthermore, an examination of its mechanisms was conducted, with a specific emphasis on the modulation of critical signaling pathways that are implicated in the progression of cancer. In thyroid cancer cells, ZIF-8 nanoparticles infused with bee venom promote programmed cell death and impair key biological processes.

References

Gulbay G, Secme M, Ilhan H . Exploring the Potential of Thymoquinone-Stabilized Selenium Nanoparticles: In HEC1B Endometrial Cancer Cells Revealing Enhanced Anticancer Efficacy. ACS Omega. 2023; 8(42):39822-39829. PMC: 10601430. DOI: 10.1021/acsomega.3c06028. View

Ilhan H . Nanoarchitectonics of the Effects of Curcumin Carbon Dot-Decorated Chitosan Nanoparticles on Proliferation and Apoptosis-Related Gene Expressions in HepG2 Hepatocellular Carcinoma Cells. ACS Omega. 2023; 8(37):33554-33563. PMC: 10515349. DOI: 10.1021/acsomega.3c03405. View

Ferrari S, Fallahi P, Galdiero M, Ruffilli I, Elia G, Ragusa F . Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. Int J Mol Sci. 2019; 20(18). PMC: 6769504. DOI: 10.3390/ijms20184413. View

Fouad Y, Aanei C . Revisiting the hallmarks of cancer. Am J Cancer Res. 2017; 7(5):1016-1036. PMC: 5446472. View

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Fagin J, Wells Jr S . Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med. 2016; 375(11):1054-67. PMC: 5512163. DOI: 10.1056/NEJMra1501993. View

Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S . Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017; 13(11):644-660. DOI: 10.1038/nrendo.2017.76. View

10.

Boumahdi S, de Sauvage F . The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. 2019; 19(1):39-56. DOI: 10.1038/s41573-019-0044-1. View

11.

Luo H, Xia X, Kim G, Liu Y, Xue Z, Zhang L . Characterizing dedifferentiation of thyroid cancer by integrated analysis. Sci Adv. 2021; 7(31). PMC: 8318367. DOI: 10.1126/sciadv.abf3657. View

12.

Raghuraman H, Chattopadhyay A . Melittin: a membrane-active peptide with diverse functions. Biosci Rep. 2006; 27(4-5):189-223. DOI: 10.1007/s10540-006-9030-z. View

13.

Fratellone P, Tsimis F, Fratellone G . Apitherapy Products for Medicinal Use. J Altern Complement Med. 2016; 22(12):1020-1022. DOI: 10.1089/acm.2015.0346. View

14.

Jamasbi E, Lucky S, Li W, Hossain M, Gopalakrishnakone P, Separovic F . Effect of dimerized melittin on gastric cancer cells and antibacterial activity. Amino Acids. 2018; 50(8):1101-1110. DOI: 10.1007/s00726-018-2587-6. View

15.

Liu C, Yang H, Zhang L, Zhang Q, Chen B, Wang Y . Biotoxins for cancer therapy. Asian Pac J Cancer Prev. 2014; 15(12):4753-8. DOI: 10.7314/apjcp.2014.15.12.4753. View

16.

El-Beltagy A, Elsyyad H, Abdelaziz K, Madany A, Elghazaly M . Therapeutic Role of Fruit and Bee Venom Against MNU-Induced Breast Cancer in Pregnant Rats and its Complications on the Ovaries. Breast Cancer (Dove Med Press). 2021; 13:431-445. PMC: 8275159. DOI: 10.2147/BCTT.S306971. View

17.

Kwon N, Sung S, Sung H, Park J . Anticancer Activity of Bee Venom Components against Breast Cancer. Toxins (Basel). 2022; 14(7). PMC: 9318616. DOI: 10.3390/toxins14070460. View

18.

Liu X, Chen D, Xie L, Zhang R . Effect of honey bee venom on proliferation of K1735M2 mouse melanoma cells in-vitro and growth of murine B16 melanomas in-vivo. J Pharm Pharmacol. 2002; 54(8):1083-9. DOI: 10.1211/002235702320266235. View

19.

Orsolic N, Knezevic A, Sver L, Terzic S, Hackenberger B, Basic I . Influence of honey bee products on transplantable murine tumours. Vet Comp Oncol. 2009; 1(4):216-26. DOI: 10.1111/j.1476-5810.2003.00029.x. View

20.

Hong S, Rim G, Yang H, Yin C, Koh H, Jang M . Bee venom induces apoptosis through caspase-3 activation in synovial fibroblasts of patients with rheumatoid arthritis. Toxicon. 2005; 46(1):39-45. DOI: 10.1016/j.toxicon.2005.03.015. View